Home/Pipeline/COV19 qcLAMP Kit

COV19 qcLAMP Kit

SARS-CoV-2 Infection

ApprovedCommercial (CE-IVD)

Key Facts

Indication
SARS-CoV-2 Infection
Phase
Approved
Status
Commercial (CE-IVD)
Company

About BIOPIX-T

Founded in 2019 as a spin-off from IMBB-FORTH, BIOPIX-T is building a diagnostics ecosystem centered on its proprietary, 3D-printed Pebble device, which performs real-time quantitative colorimetric LAMP (qcLAMP) assays. The company has achieved CE-IVD certification for its platform and associated test kits, targeting the infectious disease diagnostics market with a focus on accessibility and ease of use. Backed by venture capital and angel investors, BIOPIX-T is led by a team of scientists and professionals aiming to expand its product portfolio and global presence.

View full company profile

Other SARS-CoV-2 Infection Drugs

DrugCompanyPhase
STANDARD Q COVID-19 Ag TestSD BioSensorApproved
STANDARD M10 SARS-CoV-2 PCR KitSD BioSensorApproved